ID 816433 - BioProject

Display Settings:

Format

Summary
BioProject ID list
Accessions List

Send to:

Choose Destination

File
Clipboard
Collections
My Bibliography

Accession: PRJNA816433 ID: 816433

SARS-CoV-2 Bamlanivimab resistance sequencing

Navigate Up

This project is a component of the INSDC SARS-CoV-2 Viral Sequencing Data

Navigate Across

961 additional projects are components of the INSDC SARS-CoV-2 Viral Sequencing Data.

As part of the ACTIV-2/A5401 randomized clinical trial (NCT04518410), non-hospitalized participants with symptomatic SARS-CoV-2 infection were given bamlanivimab (700mg or 7000mg) or placebo treatment. More...

Accession	PRJNA816433
Data Type	Raw sequence reads
Scope	Multispecies
Grants	"Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)" (Grant ID UM1 AI068634, National Institute of Allergy and Infectious Diseases Extramural Activities) "Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)" (Grant ID UM1 AI068634, National Institute of Allergy and Infectious Diseases Extramural Activities) "AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections" (Grant ID UM1 AI068636, National Institute of Allergy and Infectious Diseases Extramural Activities) "AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections" (Grant ID UM1 AI068636, National Institute of Allergy and Infectious Diseases Extramural Activities) "AIDS Clinical Trial Group Laboratory Center" (Grant ID UM1 AI106701, National Institute of Allergy and Infectious Diseases Extramural Activities)
Submission	Registration date: 15-Mar-2022 Brigham and Women's Hospital
Relevance	Medical

Project Data:

Resource Name	Number of Links
Sequence data
SRA Experiments	156
Other datasets
BioSample	156

SRA Data Details

Parameter	Value
Data volume, Gbases	3
Data volume, Mbytes	1230

BioProject

Result Filters

Display Settings:

Send to:

SARS-CoV-2 Bamlanivimab resistance sequencing

Supplemental Content

Related information

Recent activity